KCM
CPRX

Kennedy Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Kennedy Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.9M Sell
856,609
-342,989
-29% -$10.1M 0.48% 43
2026
Q1 		$29.7M Sell
1,199,598
-10,094
-0.8% -$240K 0.63% 20
2025
Q4 		$28.2M Buy
1,209,692
+149,485
+14% +$3.33M 0.6% 21
2025
Q3 		$20.9M Buy
1,060,207
+50,746
+5% +$1.04M 0.46% 44
2025
Q2 		$21.9M Sell
1,009,461
-51,862
-5% -$1.22M 0.52% 30
2025
Q1 		$25.7M Buy
1,061,323
+43,657
+4% +$983K 0.61% 18
2024
Q4 		$21.2M Sell
1,017,666
-23,750
-2% -$510K 0.47% 30
2024
Q3 		$20.7M Sell
1,041,416
-234,888
-18% -$4.35M 0.46% 32
2024
Q2 		$19.8M Buy
1,276,304
+214,600
+20% +$3.34M 0.42% 42
2024
Q1 		$16.9M Buy
1,061,704
+533,802
+101% +$8.04M 0.35% 70
2023
Q4 		$8.87M Sell
527,902
-108,464
-17% -$1.48M 0.19% 197
2023
Q3 		$7.44M Buy
636,366
+333,562
+110% +$4.46M 0.18% 206
2023
Q2 		$4.07M Buy
+302,804
New +$4.36M 0.09% 337
2019
Q2 		– Sell
-999,787
Closed -$5.1M – 696
2019
Q1 		$5.1M Buy
+999,787
New +$2.94M 0.12% 323
2018
Q4 		– Sell
-1,042,645
Closed -$3.94M – 696
2018
Q3 		$3.94M Sell
1,042,645
-11,226
-1% -$35.2K 0.07% 470
2018
Q2 		$3.29M Buy
1,053,871
+237,300
+29% +$720K 0.06% 521
2018
Q1 		$1.95M Sell
816,571
-74,603
-8% -$248K 0.04% 605
2017
Q4 		$3.48M Sell
891,174
-9,444
-1% -$31.2K 0.06% 529
2017
Q3 		$2.27M Sell
900,618
-17,820
-2% -$48.9K 0.04% 594
2017
Q2 		$2.54M Buy
918,438
+687,938
+298% +$1.44M 0.05% 553
2017
Q1 		$449K Sell
230,500
-2,671
-1% -$3.4K 0.01% 697
2016
Q4 		$245K Sell
233,171
-10,065
-4% -$11.5K ﹤0.01% 703
2016
Q3 		$265K Sell
243,236
-4,475
-2% -$4.03K 0.01% 696
2016
Q2 		$176K Buy
247,711
+3,259
+1% +$2.63K ﹤0.01% 696
2016
Q1 		$286K Sell
244,452
-3,765
-2% -$5.84K 0.01% 711
2015
Q4 		$608K Sell
248,217
-854
-0.3% -$2.45K 0.01% 690
2015
Q3 		$747K Buy
+249,071
New +$1.08M 0.02% 671

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Kennedy Capital Management's CPRX Position: Q2 2026 in Review

Kennedy Capital Management reduced its Catalyst Pharmaceutical (CPRX) stake by 29% in Q2 2026, selling an estimated $10.1M and leaving 856,609 shares worth $26.9M. The position accounts for 0.48% of the portfolio, ranked #43.

Kennedy Capital Management first reported a position in CPRX in Q3 2015 and has held it in 27 quarters since. The position peaked at $29.7M in Q1 2026. 395 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Kennedy Capital Management held 856,609 shares of Catalyst Pharmaceutical worth $26.9M as of Q2 2026.
  • Kennedy Capital Management sold 342,989 Catalyst Pharmaceutical shares in Q2 2026, an estimated $10.1M.
  • Catalyst Pharmaceutical made up 0.48% of Kennedy Capital Management's portfolio in Q2 2026, its #43 holding.
  • Kennedy Capital Management first reported a position in Catalyst Pharmaceutical in Q3 2015 and has held it in 27 quarters since.
  • Kennedy Capital Management's Catalyst Pharmaceutical position peaked at $29.7M in Q1 2026.
  • 395 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.